Literature DB >> 34756729

Coronary artery calcium is associated with long-term mortality from lung cancer: Results from the Coronary Artery Calcium Consortium.

Omar Dzaye1, Philipp Berning2, Zeina A Dardari3, Daniel S Berman4, Matthew J Budoff5, Michael D Miedema6, Khurram Nasir7, Alan Rozanski8, John A Rumberger9, Leslee J Shaw10, Martin Bødtker Mortensen11, Seamus P Whelton3, Michael J Blaha3.   

Abstract

BACKGROUND AND AIMS: Coronary artery calcium (CAC) scores have been shown to be associated with CVD and cancer mortality. The use of CAC scores for overall and lung cancer mortality risk prediction for patients in the Coronary Artery Calcium Consortium was analyzed.
METHODS: We included 55,943 patients aged 44-84 years without known heart disease from the CAC Consortium. There were 1,088 cancer deaths, among which 231 were lung cancer, identified by death certificates with a mean follow-up of 12.2 ± 3.9 years. Fine-and-Gray competing-risk regression was used for overall and lung cancer-specific mortality, accounting for the competing risk of CVD death and after adjustment for CVD risk factors. Subdistribution hazard ratios (SHR) were reported.
RESULTS: The mean age of all patients was 57.1 ± 8.6 years, 34.9% were women, and 89.6% were white. Overall, CAC was strongly associated with cancer mortality. Lung cancer mortality increased with increasing CAC scores, with rates per 1000-person years of 0.2 (95% CI: 0.1-0.3) for CAC = 0 and 0.8 (95% CI: 0.6-1.0) for CAC ≥400. Compared with CAC = 0, hazards were increased for those with CAC ≥400 for lung cancer mortality [SHR: 1.7 (95% CI: 1.2-2.6)], which was driven by women [SHR: 2.3 (95% CI: 1.1-4.8)], but not significantly increased for men. Risks were higher in those with positive smoking history [SHR: 2.2 (95% CI: 1.2-4.2)], with associations driven by women [SHR: 4.0 (95% CI: 1.4-11.5)].
CONCLUSIONS: CAC scores were associated with increased risks for lung cancer mortality, with strongest associations for current and former smokers, especially in women. Used in conjunction with other clinical variables, our data pinpoint a potential synergistic use of CAC scanning beyond CVD risk assessment for identification of high-risk lung cancer screening candidates.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Cardiovascular disease; Coronary arterial calcium; Lung cancer; Prevention; Risk prediction

Mesh:

Substances:

Year:  2021        PMID: 34756729      PMCID: PMC8678296          DOI: 10.1016/j.atherosclerosis.2021.10.007

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  29 in total

1.  Coronary artery calcium can predict all-cause mortality and cardiovascular events on low-dose CT screening for lung cancer.

Authors:  Peter C Jacobs; Martijn J A Gondrie; Yolanda van der Graaf; Harry J de Koning; Ivana Isgum; Bram van Ginneken; Willem P T M Mali
Journal:  AJR Am J Roentgenol       Date:  2012-03       Impact factor: 3.959

2.  Rationale and design of the coronary artery calcium consortium: A multicenter cohort study.

Authors:  Michael J Blaha; Seamus P Whelton; Mahmoud Al Rifai; Zeina A Dardari; Leslee J Shaw; Mouaz H Al-Mallah; Kuni Matsushita; John A Rumberger; Daniel S Berman; Matthew J Budoff; Michael D Miedema; Khurram Nasir
Journal:  J Cardiovasc Comput Tomogr       Date:  2016-11-11

3.  Reliable categorisation of visual scoring of coronary artery calcification on low-dose CT for lung cancer screening: validation with the standard Agatston score.

Authors:  Yi-Luan Huang; Fu-Zong Wu; Yen-Chi Wang; Yu-Jeng Ju; Guang-Yuan Mar; Chiung-Chen Chuo; Huey-Shyan Lin; Ming-Ting Wu
Journal:  Eur Radiol       Date:  2012-12-14       Impact factor: 5.315

4.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

5.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

6.  Cigarette Smoking and Incident Heart Failure: Insights From the Jackson Heart Study.

Authors:  Daisuke Kamimura; Loretta R Cain; Robert J Mentz; Wendy B White; Michael J Blaha; Andrew P DeFilippis; Ervin R Fox; Carlos J Rodriguez; Rachel J Keith; Emelia J Benjamin; Javed Butler; Aruni Bhatnagar; Rose M Robertson; Michael D Winniford; Adolfo Correa; Michael E Hall
Journal:  Circulation       Date:  2018-04-16       Impact factor: 29.690

7.  Long-Term All-Cause and Cause-Specific Mortality in Asymptomatic Patients With CAC ≥1,000: Results From the CAC Consortium.

Authors:  Allison W Peng; Mohammadhassan Mirbolouk; Olusola A Orimoloye; Albert D Osei; Zeina Dardari; Omar Dzaye; Matthew J Budoff; Leslee Shaw; Michael D Miedema; John Rumberger; Daniel S Berman; Alan Rozanski; Mouaz H Al-Mallah; Khurram Nasir; Michael J Blaha
Journal:  JACC Cardiovasc Imaging       Date:  2019-03-15

8.  Smoking and colorectal cancer: a meta-analysis.

Authors:  Edoardo Botteri; Simona Iodice; Vincenzo Bagnardi; Sara Raimondi; Albert B Lowenfels; Patrick Maisonneuve
Journal:  JAMA       Date:  2008-12-17       Impact factor: 56.272

9.  Coronary artery calcium and the competing long-term risk of cardiovascular vs. cancer mortality: the CAC Consortium.

Authors:  Seamus P Whelton; Mahmoud Al Rifai; Zeina Dardari; Leslee J Shaw; Mouaz H Al-Mallah; Kunihiro Matsushita; John A Rumberger; Daniel S Berman; Matthew J Budoff; Michael D Miedema; Khurram Nasir; Michael J Blaha
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2019-04-01       Impact factor: 6.875

Review 10.  Inflammation and cardiovascular disease: From mechanisms to therapeutics.

Authors:  Abdulhamied Alfaddagh; Seth S Martin; Thorsten M Leucker; Erin D Michos; Michael J Blaha; Charles J Lowenstein; Steven R Jones; Peter P Toth
Journal:  Am J Prev Cardiol       Date:  2020-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.